Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Waverley PharmaTSXV:WAVE +50.00% FCF Margin % is -22.65% as of Mar. 2026. The stock has 5 warning signs investors should review. Among 950 Biotechnology companies, Waverley Pharma ranks better than 63.89% on this metric.
The historical rank and industry rank for Waverley Pharma's FCF Margin % or its related term are showing as below:
TSXV:WAVE'
s FCF Margin % Range Over the Past 10 Years
Min: -651.12 Med: -65.95 Max: -18.36
Current: -18.36
During the past 10 years, the highest FCF Margin % of Waverley Pharma was -18.36%. The lowest was -651.12%. And the median was -65.95%.
TSXV:WAVE's FCF Margin % is ranked better than 63.89% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs TSXV:WAVE: -18.36
Waverley Pharma FCF Margin % Related Terms
Waverley Pharma FCF Margin % Historical Data
* Premium members only.
The historical data trend for Waverley Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:WAVE vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Waverley Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Waverley Pharma FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Waverley Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Waverley Pharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Waverley Pharma (TSXV:WAVE) has a FCF Margin % of -22.65% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Waverley Pharma and its competitors. According to the industry distribution chart, Waverley Pharma ranks #343 out of 950 companies in the Biotechnology industry, placing it in the top 36.1%.
Is Waverley Pharma's FCF Margin % too high?
Waverley Pharma's current FCF Margin % is -22.65%. Based on the distribution chart, Waverley Pharma ranks #343 out of 950 companies in the Biotechnology industry, which is above the industry midpoint.
How does Waverley Pharma's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Waverley Pharma ranks #343 out of 950 companies for FCF Margin %. This puts Waverley Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Waverley Pharma and its competitors. Waverley Pharma's current FCF Margin % is -22.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Waverley Pharma stock overvalued right now?
Based on GuruFocus' analysis, Waverley Pharma (TSXV:WAVE) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.07, compared to a current price of C$0.02 — trading 78.6% below its estimated fair value. The current FCF Margin % is -22.65%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Waverley Pharma (TSXV:WAVE), the current FCF Margin % is -22.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics focused on oncology. The company's product pipeline includes Bortezomib, Pemetrexed, Capecitabine, and Temozolomide, among others. The company operates in one business segment, the biopharmaceutical industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:WAVE has been successfully added to your 
